Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making.
* Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
* Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
* Uses case studies to help readers understand and apply ICH guidelines
* Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
* Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
İçerik tablosu
List of Contributors ix
An Introduction to ICH Quality Guidelines: Opportunities and Challenges 1
1 ICHQ1A(R2) Stability Testing of New Drug Substance and Product and ICHQ1C Stability Testing of New Dosage Forms 3
Andy Rignall
2 Stability Testing: Photostability Testing of New Drug Substances and Products ICH Q1B 45
David Clapham
3 ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products 73
Raymond Peter Munden
4 ICH Q1E Evaluation for Stability Data 89
Garry Scrivens
5 Q2(R1) Validation of Analytical Procedures: Text and Methodology 127
Phillip Borman and David Elder
6 Impurities in New Drug Substances and New Drug Products: ICH Q3A/B: Key Guidelines in the General Impurity Management Process 167
Andrew Teasdale, David Elder, James Harvey, and Steven Spanhaak
7 ICH Q3C Impurities: Guideline for Residual Solvents 199
John Connelly
8 ICH Q3D Elemental Impurities 233
Andrew Teasdale and Sarah Thompson
9 ICH Q4: Pharmacopeial Harmonization and Evaluation and Recommendation of Pharmacopeial Texts for Use in the ICH Regions 281
David Elder
10 ICH Q5A: Viral Safety of Biotechnology Products 311
Daniel Galbraith
11 ICH Q5B Analysis of the Expression Construct in Cell Lines Used for Production of Recombinant DNA-Derived Protein Products 337
Jianxin Ye, Zhong Liu, and David Pollard
12 ICH Q5C Stability Testing of Biotechnological/Biological Products 345
John G. Davies, Di Gao, Yoen Joo Kim, Richard Harris, Patricia W. Cash, Timothy L. Schofield, Roujian Zhang, and Qiang Qin
13 Q5D Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products 375
Mark Plavsic
14 Conduct of Risk Assessments: An Integral Part of Compliance with ICH Q5A and ICH Q5D 395
Raymond W. Nims
15 ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Processes: Summary and Analysis of ICH Q5E Guideline 409
Ramani R. Raghavan and Robert Mc Combie
16 ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances 433
David Elder
17 ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products 467
Scott R. Rudge and Raymond W. Nims
18 Process-Related Impurities in Biopharmaceuticals: A Deeper Dive into Ich Q6b 487
Anil Raghani, Kim Li, Jeanine L. Bussiere, Joel P. Bercu, and Jinshu Qiu
19 ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (APIs) 509
Gordon Munro
20 Q8(R2): Pharmaceutical Development 535
Per Holm, Morten Allesø, Mette C. Bryder, and René Holm
21 ICH Q9 Quality Risk Management 579
David Elder and Andrew Teasdale
22 ICH Q10 Quality Systems: ICH Q10 Implementation at Genentech/Roche 611
Larry Wigman and Danny Ooi
23 ICH Q11: Development and Manufacture of Drug Substance 639
Ronald Ogilvie
24 ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 667
Andrew Teasdale
Index 701
Yazar hakkında
Andrew Teasdale, Ph D, is a principal scientist in pharmaceutical development with Astra Zeneca. He has over 20 years’ experience within the industry and has held a number of leadership roles both internally and externally at a cross industry level encompassing key ICH topic areas.
David Elder, Ph D, is an independent CMC consultant. He has 40 years’ experience within the pharmaceutical industry. He was formerly a director within Glaxo Smith Kline’s platform technology and science function. He is an expert member for the British Pharmacopoeia and has extensive CMC experience encompassing many of the key ICH topics.
Raymond W. Nims, Ph D, is a Senior Consultant at RMC Pharmaceutical Solutions, with experience in a variety of GMP quality assurance and quality control topics from a biologics point of reference. He has served on ad hoc panels supporting a number of USP chapters and ANSI Standards.
Aynı yazardan daha fazla e-kitap / Editör
27.827 Bu kategorideki e-kitaplar
